JAK inhibitors (Tofacitinib, Baricitinib, Upadacitinib)

Targeted synthetic DMARD (Janus kinase inhibitor)

Avoid in pregnancy — small molecules cross the placenta freely; insufficient safety data.

Evidence-based OB-GYN pharmacology reference for clinical practice and MRCOG preparation.